Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Oct;20(10):1502-1513.
doi: 10.1038/s41565-025-01981-6. Epub 2025 Sep 10.

Nanofibrous supramolecular peptide hydrogels for controlled release of small-molecule drugs and biologics

Affiliations

Nanofibrous supramolecular peptide hydrogels for controlled release of small-molecule drugs and biologics

Brett H Pogostin et al. Nat Nanotechnol. 2025 Oct.

Abstract

Maintaining safe and potent drug levels in vivo is challenging. Multidomain peptides assemble into supramolecular hydrogels with a well-defined, highly porous nanostructure that makes them attractive for drug delivery. However, their ability to extend release is typically limited by rapid drug diffusion. Here, to overcome this challenge, we present self-assembling boronate ester release (SABER) multidomain peptides capable of engaging in dynamic covalent bonding with payloads containing boronic acids. As examples, we demonstrate that SABER hydrogels can prolong the release of boronic acid-containing small-molecule drugs and boronic acid-modified biologics such as insulin and antibodies. Pharmacokinetic studies reveal that SABER hydrogels extend the therapeutic effect of ganfeborole from days to weeks, preventing Mycobacterium tuberculosis growth compared with oral administration in an infection model. Similarly, SABER hydrogels extended insulin activity, maintaining normoglycemia for 6 days in diabetic mice after a single injection. These results suggest that SABER hydrogels present broad potential for clinical translation.

PubMed Disclaimer

Conflict of interest statement

Competing interests: B.H.P., M.J.S., Z.T.B., J.D.H. and K.J.M. are co-inventors on a patent related to dynamic covalent bonding to MDPs described here. K.J.M. has received research funding support from Nanocan Therapeutics and serves as a paid consultant for the company. His work in those roles is unrelated to the content described herein. E.L.N. and S-.Y.L. received research funding support from Janssen in the past 2 years. The remaining authors declare no competing interests.

Update of

References

    1. Vargason, A. M., Anselmo, A. C. & Mitragotri, S. The evolution of commercial drug delivery technologies. Nat. Biomed. Eng. 5, 951–967 (2021). - PubMed
    1. Baryakova, T. H., Pogostin, B. H., Langer, R. & McHugh, K. J. Overcoming barriers to patient adherence: the case for developing innovative drug delivery systems. Nat. Rev. Drug Discov. 22, 387–409 (2023). - PubMed - PMC
    1. Lagreca, E. et al. Recent advances in the formulation of PLGA microparticles for controlled drug delivery. Prog. Biomater. 9, 153–174 (2020). - PubMed - PMC
    1. Kirtane, A. R. et al. Nanotechnology approaches for global infectious diseases. Nat. Nanotechnol. 16, 369–384 (2021). - PubMed
    1. Pons-Faudoa, F. P., Ballerini, A., Sakamoto, J. & Grattoni, A. Advanced implantable drug delivery technologies: transforming the clinical landscape of therapeutics for chronic diseases. Biomed. Microdevices 21, 47 (2019). - PubMed - PMC

MeSH terms

LinkOut - more resources